Long-Term Efficacy and Safety of Ustekinumab for Crohn’s Disease: Results From Im-Uniti Long-Term Extension Through two Years
William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Jean‐Frédéric Colombel(Mount Sinai Hospital), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Paul Rutgeerts(KU Leuven), Stephan R. Targan(Cedars-Sinai Medical Center), Long-Long Gao(Janssen (United States)), Subrata Ghosh(University College Cork), Willem J. de Villiers(Western University), Christopher Gasink(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Stephen B. Hanauer(Northwestern University)
Cited by 6
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k